Upcoming Login Downtime
We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.
For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Nov 24, 2021
Discovery & Translation
New mechanisms and modalities emerge for TIGIT
2021 ASH and SITC abstracts are low on data, high on innovation
BioCentury | Mar 5, 2021
Product Development
March 4 COVID Quick Takes: More guidance on vaccines for variants; plus EMA begins review of Sputnik V, Novartis-CureVac, Bharat-Ocugen, Novavax and more
The ACCESS consortium, a coalition of regulatory authorities from the U.K., Australia, Canada, Singapore and Switzerland, released guidance on Thursday outlining the data needed to approve
BioCentury | May 5, 2016
Distillery Therapeutics
Therapeutics: Tumor necrosis factor ligand superfamily member 14 (TNFSF14; LIGHT; CD258); epidermal growth factor receptor (EGFR); programmed cell death 1 ligan
BioCentury | Mar 18, 2013
Strategy
Japan's biggest biotech
KHK's scientist-CEO expanding beyond Japan with in-house tech, academic targets
Items per page:
1 - 10 of 10